<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> antibodies and anticardiolipin antibodies are acquired circulating immunoglobulins that interact with <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>These factors may exert <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties in vitro and so interfere with coagulation tests that use <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>These antibodies are not, however, associated with a <z:e sem="disease" ids="C0019087" disease_type="Disease or Syndrome" abbrv="">hemorrhagic diathesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Indeed, despite their name and their in vitro <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties, they have been associated right from the earliest reports with systemic and cerebral thromboembolic episodes </plain></SENT>
<SENT sid="4" pm="."><plain>We report the clinical and instrumental findings in a patient with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> antibodies in the serum </plain></SENT>
</text></document>